Heart Failure Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape. Summary. This reports provides a data-driven overview of the current and future competitive landscape in HF therapeutics.
New York, March 27, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Heart Failure Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06435631/?utm_source=GNW
There are more than 45.9 million diagnosed prevalent cases of heart failure in the 16 major markets.
There is a significant number of marketed innovator drugs for the treatment of HF, mostly belonging to enzyme inhibitors and receptor antagonists category.
R&D activity in HF is robust globally, with five products in the pre-registration stage and 17 products in Phase III development.
Commercial sponsors dominate clinical trial development in HF, with the US emerging as the key market for conducting Phase III trials in HF.
During the past 12 months, seven merger and acquisition transactions and six strategic alliances involving HF assets were successfully completed.
Although there are many emerging players in the pipeline developing novel products for HF, no commercial launch is expected to happen in the HF drugs market over the next 12 months.
Scope
Heart Failure (HF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the HF market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HF market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06435631/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
